Lymphoma Research Foundation

The Lymphoma Research Foundation’s story is told by many different voices: we are patients, survivors, care partners, researchers, healthcare providers, and supporters all focused on one shared vision. By bringing together the promise of science and the power of people, a future without lymphoma is within our reach. Our new look represents our continued commitment: a singular focus across the many subtypes of lymphomas and the many members of our community: https://ow.ly/VtRk50S17G5

Congratulations to the Lymphoma Research Foundation's Scientific Advisory Board Chair-Elect Dr. Andrew M. Evens, DO, MBA, MSc (Rutgers Cancer Institute) on being elected to the American Society of Hematology's (ASH) inaugural ASH Research Collaborative Board of Directors! Read more about this prestigious appointment and about the ASH Research Collaborative's mission: https://lnkd.in/enmCYZ2p

On June 26, 2024, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. To learn more about this approval, visit: https://lnkd.in/gy-Y9nSM

In 2008, the Lymphoma Research Foundation expanded its first-in-class lymphoma education programming and developed Lymphoma Rounds. Almost two decades since its inaugural program, we're reflecting on the impact that Lymphoma Rounds has had on the healthcare professional community in the latest issue of Pulse: https://lnkd.in/eKtWytGk

In many ways, Timmy Ward is a typical college senior, majoring in sociology and playing football for the Rutgers University Scarlet Knights – a Big Ten powerhouse. However, what most people don’t know is what he has had to overcome to get here. Discover more about Timmy's experience after being diagnosed with lymphoma in the latest Pulse: https://lnkd.in/e-qda_g2

Survivorship goes beyond the end of cancer treatment - it's a long-term journey. Cancer survivors have unique needs and distinct challenges, making the field of survivorship research critical, especially for lymphoma survivors. Lymphoma Research Foundation CEO Meghan Gutierrez shares more about the survivor experience and the road ahead for cancer survivorship research in this article in Cure (Targeted Oncology): https://lnkd.in/gvWSJ_zC

The Lymphoma Research Foundation is proud to announce its 2024 grant class – 28 research grants awarded to scientists based at many of the world’s leading cancer research institutions – totaling more than $3.5 million in innovative lymphoma and chronic lymphocytic leukemia (CLL) research. Meet our 2024 grantee class in the latest issue of Pulse: https://lnkd.in/gM_nyG4C

Sending gratitude to the amazing team at Morgan Stanley who volunteered and made the Lymphoma Research Foundation New York Lymphoma Walk a meaningful experience for our patients and their families. Thank you for supporting our mission to eradicate #lymphoma and people whose lives have been touched by a cancer diagnosis. #Teamwork 

Thomas Habermann, MD (Mayo Clinic), former Chair of the Lymphoma Research Foundation’s Scientific Advisory Board (SAB), brings passion and drive to every study he works on and every patient he works with. Discover more about the advancements in lymphoma care he's made possible in the latest issue of Pulse: https://lnkd.in/ed_TyWr7

This week is #NationalBlackFamilyCancerAwarenessWeek. Caring for a loved one with lymphoma can bring its own unique challenges and questions. Learn more about communicating with your loved one's healthcare team and caregiver coping skills at our upcoming webinar on July 24: https://lnkd.in/ecAP3afi